Navigation Links
FASgen Announces New Discovery for Treatment of Stroke

BALTIMORE, Dec. 20 /PRNewswire/ -- FASgen is pleased to announce the recent publication of important results from research into a potential treatment for stroke using one of FASgen's proprietary compounds, C75. The Company is a leader in the research in the field of FASi (fatty acid synthase inhibition). One area of that research has been for the treatment of metabolic disease disorders, including obesity. As the regulation of appetite is centered in the hypothalamus in the brain, research was undertaken to evaluate the safety of the Company's compounds in the brain. An unexpected and significant discovery resulted when the studies demonstrated not only that the compounds were non-toxic in the brain, but also they had the positive effect of providing significant neuroprotection in the case of ischemic stroke. In the stroke models tested, the Company's compound C-75 reduced AMPK levels and resulted in neuroprotection by reduced stroke damage, even when administered poststroke. These remarkable findings were recently published in the article, "Neuroprotective Effects of Adenosine Monophosphate-Activated Protein Kinase Inhibition and Gene Deletion in Stroke," McCullough et al, Stroke 2007, 38; 2992-2999 (December 11, 2007).

About FASgen, Inc.: FASgen, Inc. is a drug development company founded in 2000 by four distinguished Johns Hopkins researchers to create new therapeutic products based on the selective inhibition of fatty acid biosynthesis. The Company has the exclusive license from Johns Hopkins to more than 15 years of research in the field, which research continues under a sponsored research agreement with the University.

The Company has designed and synthesized many compounds that selectively inhibit fatty acid biosynthesis. One group of these compounds holds great promise for new highly specific therapeutics for cancer; additional compounds have the potential of specific therapeutics for obesity and related metabolic disorders; and, an additional group of compounds have the potential of specific therapeutics for TB, including multiple drug resistant TB (MDR-TB) and latent TB infections that affect one third of the world's population. For more information, visit FASgen's website at

Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. FASgen Announces Significant Milestone in Its Cancer Drug Development Program
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
(Date:11/30/2015)... , Nov. 30, 2015  QT Vascular Ltd., ... and together with its subsidiaries, TriReme Medical LLC and ... company engaged in the design, assembly and distribution of ... vascular disease, is pleased to announce that a three-judge ... Court of Appeals for the Federal Circuit ("Federal Circuit") ...
(Date:11/30/2015)... 2015   Royal Philips  (NYSE: PHG ... Radiology Solutions, a fully integrated, consultative approach to ... data-driven practice management approaches that combine imaging systems, ... improve care delivery and reduce costs. Making its ... North America Annual Meeting (RSNA) in ...
(Date:11/30/2015)... -- Nautilus Medical Inc. today announced worldwide availability of ... ). The release of MatrixRay to the entire medical ... North America) in Chicago - ... --> --> MatrixRay is the ... studies worldwide via a peer-to-peer exchange network of physicians ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... Olympic Gold Medalists and Celebrity ... brands across various categories through traditional and social media marketing campaigns and other ... of Gold Medal Moms who can connect with today’s most important consumer: mothers. ...
(Date:11/30/2015)... ... December 01, 2015 , ... The ... a 2015-2016 inductee into its VIP Woman of the Year Circle. She is ... leading networking organization exclusively for professional women, boasting 850,000 members and over 200 ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... (Meso Foundation) released information for caregivers and held two webinars on topics of ... on demand free of charge at . , With a loved ...
(Date:11/30/2015)... ... November 30, 2015 , ... MOSI recently added two state-of-the-art augmented reality (AR) ... the Jurassic to their collection of interactive exhibits within the Kids In Charge! building. ... allow guests to get closer than ever to a range of animals as they ...
(Date:11/30/2015)... VA (PRWEB) , ... November 30, 2015 , ... ... mesothelioma-affected community across the United States to access life-saving information provided ... Malignant Mesothelioma will consist of three individual conferences in three major cities: ...
Breaking Medicine News(10 mins):